Aeglea BioTherapeutics (AGLE) Acquires Spyre Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD).
Aeglea BioTherapeutics (AGLE) Reports Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to. | April 12, 2023
Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels
Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May. | April 12, 2023